10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% — 3-year update

Authors :: S. Kilickap
M. Özgüroğlu
A. Sezer
M. Gumus
I. Bondarenko
M. Gogishvili
H.M. Türk
I. Cicin
D. Bentsion
O.A. Gladkov
P. Clingan
V. Sriuranpong
X. He
J-F. Pouliot
F. Seebach
I. Lowy
G. Gullo
P. Rietschel
Source :: Journal of Thoracic Oncology. 18:S42-S43
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.

Tools